血竭治疗溃疡性结肠炎临床研究  

Clinical treatment of ulcerative colitis with Sanguis Draxconis

作　　者：李敏[1] 唐学贵[1] 吴至久[1] 杨勇军[1] 何德才[1] 王争理[1] 杜丽娟[1] 

机构地区：[1]川北医学院附院肛肠科,四川南充637000

出　　处：《中成药》2007年第7期956-959,共4页Chinese Traditional Patent Medicine

基　　金：四川省中管局课题(合同号2004B08)

摘　　要：目的:为观察血竭治疗溃疡性结肠炎(UC)的疗效和不良反应。方法:采用血竭口服及保留灌肠治疗UC患者81例,并与柳氮磺胺吡啶口服及保留灌肠治疗UC患者81例对照。结果:治疗组完全缓解率为24.69,总有效率67.90。对照组中9例因不良反应未完成疗程,完全缓解率为25.00,总有效率为72.22,两组无显著差异(P>0.05),但两组不良反应有显著差异(P<0.05)。结论:血竭与柳氮磺胺吡啶治疗溃疡性结肠炎,疗效相近,但前者不良反应明显少于后者。AIM： To observe the curative effect and adverse drup reaction （ADR） of Sanguis Draxconis in the treatment of ulcerative colitis （UC）. METHODS ： 81 cases with UC were given peroral and retention-enema with Sanguis Draxconis. They were compered with another 81 cases which were given peroral and retention-enema with SASP. RESULTS： The curative rate and total effective rate were 24.69% and 67.90% respectively in the treatment group, 25.00% and 72.22% respectively in the controlled group. There was not a great difference between the two groups （ P 〉 0.05 ）. But the ADR was a great difference （ P 〈 0.05 ）. 9 cases did not complete the trial because of ADR in the controlled group. CONCLUSION： The efficacy of Sanguis Draxconis and SASP were similar in the treatment of ulcerative colitis, but the ADR of the former are significantly less than that of the later.

关 键 词：血竭 溃疡性结肠炎 柳氮磺胺吡啶 

分 类 号：R287[医药卫生—中药学]